Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
BRITISH JOURNAL OF HAEMATOLOGY, cilt.198, sa.6, ss.988-993, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 198 Sayı: 6
- Basım Tarihi: 2022
- Doi Numarası: 10.1111/bjh.18233
- Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
- Sayfa Sayıları: ss.988-993
- Anahtar Kelimeler: relapsed or refractory multiple myeloma, proteasome inhibitor, carfilzomib, cytogenetics, CARFILZOMIB, DEXAMETHASONE
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.